Cancer biomarker Market Research Report- Global Forecast till 2030

Cancer Biomarker Market Research Report: By Types (Protein Biomarker, Genetic Biomarker), By Applications (Diagnostic, Prognostic, Therapeutic), By End Users (Pharmaceutical and Biotechnology Companies, Diagnostic Companies) – Forecast till 2030

ID: MRFR/Pharma/3935-CR | January 2018 | Region: Global | 85 Pages         

1 Report Prologue

2 Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3 Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4 Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6 Global Cancer Biomarker Market, By Types

6.1 Introduction

6.2 Protein Biomarker

6.3 Genetic Biomarker

6.4 Others

7 Global Cancer Biomarker Market, By Application

7.1 Introduction

7.2 Diagnostic

7.2.1 Imaging

7.2.2 Non- Imaging

7.3 Prognostic

7.4 Therapeutic

8 Global Cancer Biomarker Market, By End Users

8.1 Introduction

8.2 Pharma & Biotech Companies

8.3 Diagnostic Tool Companies

8.4 Healthcare IT/Big Data Companies

8.5 Clinical Laboratories

9 Global Cancer Biomarker Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 F. Hoffmann-La Roche AG

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Becton Dickinson

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 PerkinElmer, Inc.

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Bristol-Myers Squibb

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Bio-Rad Laboratories

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Eli Lilly and Company

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Merck & Co., Inc

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Pfizer Inc.

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.10 GlaxoSmithKline plc.

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 QIAGEN N.V

11.11.1 Company Overview

11.11.2 Financials

11.11.3 Products

11.11.4 Strategy

11.11.5 Key Developments

 11.12 Novartis AG

11.12.1 Company Overview

11.12.2 Financials

11.12.3 Products

11.12.4 Strategy

11.12.5 Key Developments

11.13 Thermo Fisher Scientific Inc.

11.13.1 Company Overview

11.13.2 Financials

11.13.3 Products

11.13.4 Strategy

11.13.5 Key Developments

11.14 Illumina Inc.

11.14.1 Company Overview

11.14.2 Financials

11.14.3 Products

11.14.4 Strategy

11.14.5 Key Developments

11.15 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Medical End Users Industry

Chapter 13 Appendix

12 List of Tables

Table 1 Cancer Biomarker Industry Synopsis, 2020 – 2027

Table 2 Global Cancer Biomarker Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Cancer Biomarker Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 5 Global Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 6 Global Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 8 North America Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 9 North America Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 10 US Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 11 US Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 12 US Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Market by Type, 2020 – 2027, (USD Million)

Table 14 Canada Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 15 Canada Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 17 South America Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 18 South America Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 19 Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 20 Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 21 Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 23 Western Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 24 Western Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Cancer Biomarker Market by Type, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Cancer Biomarker Market by Application, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Cancer Biomarker Market by End Users, 2020 – 2027, (USD Million)

13 List of Figures

Figure 1 Research Process

Figure 2 Segmentation for Global Cancer Biomarker Market

Figure 3 Segmentation Market Dynamics for Global Cancer Biomarker Market

Figure 4 Global Cancer Biomarker market Share, by Type 2020

Figure 5 Global Cancer Biomarker market Share, by Application 2020

Figure 6 Global Cancer Biomarker Market Share, by End Users, 2020

Figure 7 Global Cancer Biomarker Market Share, by Region, 2020

Figure 8 North America Cancer Biomarker Market Share, by Country, 2020

Figure 9 Europe Cancer Biomarker Market Share, by Country, 2020

Cancer Biomarker Market

Cancer Biomarker Market Booming at a CAGR of 11.9% to hit $ 27,108.54 Million by 2030

Segmentation

By Types Protein Biomarker Genetic Biomarker
By Applications Diagnostic Prognostic Therapeutic
By End Users Pharmaceutical And Biotechnology Companies Diagnostic Companies

Key Players

  • Becton Dickinson (U.S.)
  • Merck & Co.Inc. (U.S.)
  • Novartis AG (Switzerland)
  • PerkinElmer Inc. (U.S.)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Bio-Rad Laboratories (U.S.)
  • Illumina Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Abbott Laboratories (U.S.)
  • GlaxoSmithKline plc. (U.S.)

Drivers

  • Adoption of Western lifestyle by developing economies and extensive research on cancer biomarkers
Speak to Analyst Request a Free Sample

Cancer Biomarker Market Overview


The cancer biomarker market is predicted to expand market value at a CAGR of 12.10% between the analysis period of 2020 to 2030. Further, the same market is estimated to generate a significant market size during the research period. In general, Cancer is considered to be a diverse disease that can occur in various tissues and organs. This different cancer condition relates to various risk factors. Here, the cancer biomarkers are known to be the molecules that are released in the presence of a tumor or a particular cancer indication in the human body. It usually indicates the presence of cancerous cells in the body, which can be either in the form of a molecule, substance, or a physical event. Generally, these molecules are found in serum, tissues, blood, urine, and other body fluids that mention a disease or any abnormal process. 


In recent past years, an alarming surge in Cancer has been evident in the worldwide population. It has been found that nearly 14 million new cases of cancer have been reported every year. As per the World Health Organisation (WHO) report, nearly22 a million new cases of cancer were reported in 2012, which is predicted to increase further by 70% over the next two decades. 


The Cancer biomarker Market Forecast report highlights that the global market is highly contributed with the support of the intended audiences. The intended audiences of the market include:



  • Government and private research companies.

  • Pharmaceutical companies.

  • Medical research laboratories.

  • Drug manufacturers and suppliers.

  • Research and development (R&D) companies. 


COVID-19 Analysis


The Cancer Biomarker Market Growth has been impacted in the first half of 2020 because of the unprecedented covid-19 pandemic situation across the world. At this time, the lack of transportation, lack of workforce, disruption in the manufacturing chain and manufacturing chain has been evident. The lockdown and shutdown have made people stay inside houses which have stopped many people from getting diagnosed and treated. However, the imposed restriction has decreased the implication of testing. 


Therefore, the market players have thrown light on constituting early detection and effective preventive measures. Presently, the Cancer biomarker Market is projected to generate a larger market share in the further coming years. 


Chief Factors Existing In The Market



  • Key Market Drivers


The cancer biomarker market is driven because of many factors like extensive research of cancer biomarkers, rising adoption of western lifestyles in the developing regions, improved precision and speed of diagnosis, and encouragement for the development of biomarkers by the FDA. 


Moreover, the development of highly specific drugs and rising funding relating to cancer-related research by the private and government sectors are boosting the global market growth during the research period. 



  • Market Challenges


The cancer biomarker market might face bigger challenges because of the low benefit-cost ratio and high investments relating to cancer biomarkers development. 


Moreover, the strident rules and regulations of the government relating to the cancer biomarker can be one of the biggest challenges to the growth of the worldwide market during the review period. 



  • Market Opportunities


The cancer biomarker market is projected to bring lucrative opportunities due to the rising investment through private and government funds in cancer-related research.


Moreover, the development of highly specific drugs relating to Cancer is projected to bring significant opportunities for the manufacturers and key players during the forecast timeframe. 



  • Market Restraints


The cancer biomarker market might experience restraint because of the higher health care cost for the treatment of cancer across the globe. Cancer treatment is not affordable for many patients who are going through Cancer. Thus, the need for immediate processing and issues of reimbursement is projected to hinder the growth of the global market. 


In addition, the market might get affected because of the low success rate of clinical trials of biomarkers. 


Cumulative Evaluation of The Market


The Cancer biomarker Market Size has shown potential growth in the past few years and is further predicted to acquire a significant market size in the further coming years. 


However, the present market consists of strong market players who are working effectively to thrive on the current market performance of the market. These kinds of efforts can enhance market growth in the upcoming years. 


Market Segmentation


As per the Cancer biomarker Market Outlook report, the current market has been segmented in terms of types, end-users and applications. 



  • By Types:


In terms of the type segment, the market has been classified into genetic biomarkers, protein biomarkers, and others.


All the intended audiences prefer all these types on the basis of their functionality. 



  • By disease: 


The cancer biomarker market has been segmented based on Cervical Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and other diseases.


Of these, lung cancer is predicted to old the largest Market Share during the forecast timeframe. 



  • By End-User:


Depending on the end-user segment, the market has been segmented into diagnostic tool companies, pharmaceutical and biotechnology companies, clinical laboratories, healthcare big data companies, and others. 


The end-users preferred the product Cancer biomarker based on their needs and requirements. 



  • By Application:


Based on the application segment, the worldwide Cancer biomarker Market has been categorized into prognostic, cancer diagnostic, and therapeutic. 


Further, the cancer diagnostic is sub-categorized into non-imaging and imaging. 


Regional Analysis


According to Cancer biomarker Market Analysis, the global market covers various regions like Europe, America, the Middle East & Africa, Asia Pacific, and others. 


Out of all, the North American market for Cancer biomarkers is anticipated to acquire the largest market share during the forecast timeframe of 2025. This region is growing due to the rising investments by the key players considering the diagnosis and detection of cancer and the high prevalence of cancer across the region. In this region, the United States is projected to lead the market because of the rising prevalence rate of Cancer, increasing investment in research and development, and major regions considering medical tourism. Moreover, this region is highly contributed because of the rising demand for personalized medicine, growing government support for the development and discovery of biomarkers, increasing biomarkers usage in drug discovery among the pharmaceutical companies, and adoption of advanced omics technologies to discover biomarkers in the region. 


Apart from all, the European market for Cancer biomarkers is showing significant market share during the analysis period due to the availability of funds for research and the rising number of clinical trials in the region. The countries like France, the U.K., and Germany are growing demand for new diagnostic tools and devices in the region, fuelling the cancer biomarker Market Value. 


Competitive Intensity Within the Industry


Many competitors are playing a significant role in thriving the performance of the market for cancer biomarkers. These market leaders are: 



  • Becton Dickinson (U.S.),

  • Merck & Co., Inc. (U.S.),

  • Novartis AG (Switzerland),

  • PerkinElmer, Inc. (U.S.),

  • F. Hoffmann-La Roche AG (Switzerland), 

  • Bio-Rad Laboratories (U.S.),

  • Illumina Inc. (U.S.),

  • Thermo Fisher Scientific Inc. (U.S.),

  • Abbott Laboratories (U.S.), 

  • GlaxoSmithKline plc. (U.S.),

  • Bristol-Myers Squibb (U.S.), 

  • Eli Lilly and Company (U.S.), 

  • Pfizer Inc. (U.S.), 

  • QIAGEN N.V. (U.S.).


According to the Cancer biomarker Market Trends report, these market leaders are present across the world and applying new ideas and strategies to boost the market growth in the forecast period. These market leaders are focusing on research and developmental initiatives to thrive the global market performance across the world. 


Recent Market Developments



  • In December 2020, FDA gave approval to the NGS-based companion diagnostic of the prominent company Thermo Fisher Scientific (U.S.). It has aimed to provide EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.

  • In April 2021, Elecsys Anti-p53 immunoassay was launched by the prominent player F. Hoffmann-La Roche Ltd. (Switzerland). It has been proposed to aid the diagnosis of different types of Cancer.


Report Overview


As per the Cancer biomarker Market report, significant market growth has been evident in the past few years and is predicted o continue the same. This report has thrown light on the regional analysis, competitive analysis, market overview, market segmentation, Covid-19 analysis, and market dynamics. 


Further, this report has highlighted the recent development in the present market to understand its marketing performance across the world. 


Key Industrial Segments


By Types:



  • genetic biomarker, 

  • protein biomarker, 

  • others


By disease: 



  • Cervical Cancer, 

  • Breast Cancer, 

  • Prostate Cancer, 

  • Colorectal Cancer, 

  • Lung Cancer, 

  • other diseases


By End-User:



  • diagnostic tool companies, 

  • pharmaceutical and biotechnology companies, 

  • clinical laboratories, 

  • healthcare big data companies, 

  • others


By Application:



  • prognostic, 

  • cancer diagnostic, 

  • therapeutic



Report Scope:
Report Attribute/Metric Details
  Market Size   2030 : Significant Value
  CAGR   12.10% (2020 - 2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Types, Applications, End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   F. Hoffmann-La Roche AG (Switzerland), Becton Dickinson (U.S.), Abbott Laboratories (U.S.), PerkinElmer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), Bio-Rad Laboratories (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.S.), QIAGEN N.V (U.S.), Novartis AG (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Illumina Inc. (U.S.)
  Key Market Opportunities   High investment through government and private funds in cancer-related research, and development of highly specific drugs
  Key Market Drivers   Adoption of Western lifestyle by developing economies and extensive research on cancer biomarkers


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Global market is expected to expand at 12.10% CAGR from 2020 to 2030.

Adoption of Western lifestyle by developing economies and extensive research on cancer biomarkers are primary drivers .

High costs of cancer treatment is the major factor expected to impede the global market growth.

The Americas is expected to dominate in the global market till 2023 due to investments in cancer diagnosis and high incidence of cancer.

Thermo Fisher Scientific Inc., PerkinElmer, Inc., Bristol-Myers Squibb, Pfizer Inc., Illumina Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Becton Dickinson, GlaxoSmithKline plc., QIAGEN N.V, Eli Lilly and Company, Novartis AG, Abbott Laboratories, and Bio-Rad Laboratories are prominent players of the global market.